Emergent BioSolutions (EBS) Misses Q2 EPS, Revenue
Tweet
Share
E-mailGet Alerts EBS Hot Sheet
Price: $6.72 +2.60%
Revenue Growth %: -45.6%
Financial Fact:
Weighted-average number of shares - basic: 40.47M
Today's EPS Names:
OCCI, ALZN, ASPU, More
Revenue Growth %: -45.6%
Financial Fact:
Weighted-average number of shares - basic: 40.47M
Today's EPS Names:
OCCI, ALZN, ASPU, More
Join SI Premium – FREE
Emergent BioSolutions (NYSE: EBS) reported Q2 EPS of ($0.86), $1.24 worse than the analyst estimate of $0.38. Revenue for the quarter came in at $242.7 million versus the consensus estimate of $270.94 million.
For earnings history and earnings-related data on Emergent BioSolutions (EBS) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- AI and earnings keep driving markets as focus shifts to Trump-Xi summit
- UBS Reiterates Neutral Rating on Pilgrim's Pride (PPC) on 'Challenging' Near-Term Fundamentals
- Exelon (EXC) PT Lowered to $49 at Argus
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
